“Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback